Innovating Cure & Care to make patients’ lives better

Zambon Group
The group

We are a modern chemical-pharmaceutical company, founded on the history and values of an Italian family owned enterprise, with ambitious plans for growth


The Group

We look to the future, researching new cure and treatment solutions for specialized diseases such as Parkinson's and severe respiratory disease

Zambon USA Ltd.

Zambon’s Presence in the USA

Over the past few years, we have been steadily building our presence in the US through acquisition, R&D efforts, collaborative partnerships, and relationships with top scientific leaders, policymakers and patient organizations.



Bronchiolitis Obliterans Syndrome (BOS) is a rare and severe respiratory disease that commonly affects people following lung or allogeneic hematopoietic stem cell transplant.



Non-cystic Fibrosis Bronchiectasis (NCFB) is a serious respiratory disease characterized by chronic inflammation, wall thickening and dilatation of the airways.

WOrk with us

Work with us

We want people who make the difference through a make-it-happen approach based on company ethics. We recognize merits, developing talents and taking good care of our people.

Woman reading online news on digital tablet

News & Media

  • May 12, 2022 - Zambon Announces Attendance at American Thoracic Society (ATS) 2022 Annual Meeting
    Download press release
  • Zambon to present data on lung transplantation trends and survival rates in Europe at ISHLT 2022
    Read more
  • Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb® in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFB)
    Read more
  • Positive Results from Phase 3 PROMIS-I Study of CMS I-neb® in Patients with Non-Cystic Fibrosis Bronchiectasis Presented at European Respiratory Society (ERS) Annual Meeting
    Read more

View additional News & Media


Webinars & Podcasts

The replay of the ATS webinar sponsored by Zambon USA: “A Deep Dive into the “I”s of Non-cystic fibrosis bronchiectasis” that aired June 13th will be available on or about June 27th.

ATS On Demand Webinar “Looking Into the “I”s of NCFB” is now available until June 24th! Available to all ISHLT 2022 attendees. To access and sign in, click:



Lung Transplant Foundation
Virtual Meeting on BOS

The Lung Transplant Foundation is holding an externally-led patient-focused drug development meeting on Bronchiolitis Obliterans Syndrome. The virtual meeting will take place on Wednesday, June 22, 2022 from 10:00 AM – 3PM ET. For additional information and to register, visit here.


Visit Us

We will be at CHEST 2022 in Nashville, TN! 
October 16-19, 2022, Booth #1223